Ignite Creation Date:
2024-05-06 @ 8:20 PM
Last Modification Date:
2024-10-26 @ 3:25 PM
Study NCT ID:
NCT06344780
Status:
RECRUITING
Last Update Posted:
2024-04-03
First Post:
2024-03-28
Brief Title:
Abemaciclib Palbociclib or Dalpiciclib Combined With Endocrine Therapy as First-line Treatment in HR Positive HER2 Negative Unresectable or Metastatic Breast Cancer
Sponsor:
Fudan University
Organization:
Fudan University
Organization Data
Organization:
Fudan University
Class:
OTHER
Study ID:
YOUNGBC-28
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Fudan University
Lead Sponsor Class:
OTHER
Responsible Party:
Biyun Wang MD
Responsible Party Title:
Professor
Responsible Party Type:
PRINCIPAL_INVESTIGATOR
Responsible Party Affiliation:
Fudan University
Old Name:
None
Old Organization:
None